The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation.
 
Kenneth H. Yu
Consulting or Advisory Role - Ipsen
Research Funding - General Oncology (Inst); Ipsen; OncoC4 (Inst); Senhwa Biosciences (Inst)
 
Colin D. Weekes
Honoraria - Bayer; Celgene; Lilly
Consulting or Advisory Role - Celgene; Ipsen; Merrimack
Research Funding - Actuate Therapeutics; AstraZeneca; Celgene; Dicephera Pharmaceuticals, Inc.; Genentech/Roche; Novartis
 
Yi-Bin Albert Chen
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Celularity; Daiichi Sankyo/Lilly; Equillium; Incyte; Jasper Therapeutics; Magenta Therapeutics
 
Jeffrey Aaron Glazier
Employment - General Oncology
Leadership - General Oncology
Stock and Other Ownership Interests - General Oncology
Patents, Royalties, Other Intellectual Property - General Oncology (Inst)
 
Arnold Glazier
Employment - General Oncology
Leadership - General Oncology
Stock and Other Ownership Interests - General Oncology
Patents, Royalties, Other Intellectual Property - General Oncology (Inst)
 
Parastoo Dahi
Consulting or Advisory Role - Kite, a Gilead company
 
Sergio Giralt
Honoraria - Amgen; Celgene; Jazz Pharmaceuticals; Sanofi; Takeda
Consulting or Advisory Role - Actinuum; Amgen; Bristol-Myers Squibb; Celgene; Janssen; Jazz Pharmaceuticals; Johnson & Johnson; Pfizer; Sanofi; Takeda
Research Funding - Actinuum; Amgen; Celgene (Inst); Johnson & Johnson; Miltenyi Biotec (Inst); Sanofi; Takeda
Travel, Accommodations, Expenses - Amgen; Celgene; Jazz Pharmaceuticals; Sanofi
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca; Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen; Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma